BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12171721)

  • 1. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Friends, faithfulness and fortunes.
    Hale G
    Cytotherapy; 2001; 3(3):135-6. PubMed ID: 12171720
    [No Abstract]   [Full Text] [Related]  

  • 4. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab in stem cell transplantation.
    Hale G
    Med Oncol; 2002; 19 Suppl():S33-47. PubMed ID: 12180491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Chakraverty R; Orti G; Roughton M; Shen J; Fielding A; Kottaridis P; Milligan D; Collin M; Crawley C; Johnson P; Clark A; Parker A; Bloor A; Pettengell R; Snowden J; Pettitt A; Clark R; Hale G; Peggs K; Thomson K; Morris E; Mackinnon S
    Blood; 2010 Oct; 116(16):3080-8. PubMed ID: 20587785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K; Wilson WH
    Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract]   [Full Text] [Related]  

  • 10. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation.
    Novitzky N; Rouskova A
    Cytotherapy; 2001; 3(3):165-73. PubMed ID: 12171723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.
    Bunjes D
    Transfus Sci; 2000 Oct; 23(2):151-62. PubMed ID: 11035276
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
    Reams BD; Davis RD; Curl J; Palmer SM
    Transplantation; 2002 Sep; 74(6):903-4. PubMed ID: 12364881
    [No Abstract]   [Full Text] [Related]  

  • 14. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa.
    Focarelli R; Francavilla S; Francavilla F; Della Giovampaola C; Santucci A; Rosati F
    Mol Hum Reprod; 1999 Jan; 5(1):46-51. PubMed ID: 10050661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
    Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAMPATH-1H in the treatment of autoimmune cytopenias.
    Marsh JC; Gordon-Smith EC
    Cytotherapy; 2001; 3(3):189-95. PubMed ID: 12171725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM; Li Y; Yu C; Li N; Li JS
    Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.